The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
Tina Cascone
Honoraria - Society for Immunotherapy of Cancer
 
Kenneth R. Hess
No Relationships to Disclose
 
Ishwaria Mohan Subbiah
No Relationships to Disclose
 
Sarah Nelson
No Relationships to Disclose
 
Naoto Morikawa
No Relationships to Disclose
 
Monique B. Nilsson
No Relationships to Disclose
 
Tarak Bhatt
No Relationships to Disclose
 
Siraj Ali
No Relationships to Disclose
 
William Nassib William
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
 
Victoria M. Raymond
Employment - Guardant Health; Trovagene
Stock and Other Ownership Interests - Guardant Health; Trovagene
 
Richard B. Lanman
Employment - Guardant Health; Veracyte
Leadership - Biolase; Guardant Health
Stock and Other Ownership Interests - Biolase; Guardant Health
Research Funding - Guardant Health
 
David Paul Carbone
No Relationships to Disclose
 
Ravi Salgia
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Eisai; Eisai; G1 Therapeutics; Lilly; MedImmune; Novartis; Sandoz; Seagen; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
George R. Simon
Honoraria - AstraZeneca; Celgene
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Celgene; Genentech/Roche; Lilly; Merck Serono
Speakers' Bureau - AstraZeneca; Celgene
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - ARIAD; Celgene; Genentech/Roche; Lilly; Merck Serono
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals; Samsung Bioepis
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Honoraria - ARIAD; AstraZeneca; Guardant Health; Pfizer; Spectrum Pharmaceuticals; Takeda; Trovagene
Consulting or Advisory Role - AstraZeneca; GreenPeptide; Ignyta; OncoMed; Pfizer; Trovagene
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - ARIAD; Guardant Health; Ignyta
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)